Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where ...

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

Somapacitan can be used, within its marketing authorisation, as an option to treat growth failure caused by growth hormone deficiency in people 3 to 17 years. Somapacitan can be used if the company ...

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. This topic was considered as a cost comparison evaluation by the lead team of the highly specialised ...

Somapacitan (Sogroya, Novo Nordisk) is indicated 'for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Somapacitan (Sogroya) is available on the NHS. It is a possible treatment for growth failure caused by growth hormone deficiency in people 3 to 17 years. Is this treatment right for me or my child?

Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199] Medicine Awaiting decision TBC ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The appraisal committee has prepared final draft guidance (FDG) on Dapagliflozin for treating chronic kidney disease (review of TA775) and submitted it to NICE. The FDG has been sent to consultees for ...